Last updated: April 19, 2026
What is the scope of patent KR102901189?
The patent KR102901189 covers a specific pharmaceutical composition and its use. It primarily focuses on a drug formulation involving a novel compound or combination designed to enhance therapeutic efficacy or reduce side effects. The scope extends to formulations, methods of manufacturing, and specific use applications related to the active ingredient.
- The patent claims protection over chemical entities or combinations with specific structural features, as indicated in the claim set.
- It encompasses methods of administration and treatment methods utilizing the claimed compounds.
- The scope also potentially includes derivatives, salts, esters, or formulations derived from the core active ingredient.
Patent family breadth
The patent belongs to a patent family that likely includes counterparts in other jurisdictions. It focuses on compound synthesis, formulation, delivery, and specific therapeutic indications.
What are the main claims of KR102901189?
The core claims in KR102901189 include:
- Compound Composition: Claims cover a chemical compound with detailed structural formulas, such as a specific heterocyclic ring or substituents. These formulas are described with precise atom arrangements and functional groups.
- Formulation Claims: Claims extend to pharmaceutical compositions comprising the claimed compound, including carriers and excipients.
- Method of Use: Claims describe medical methods involving administering the compound to treat a specific condition, such as cancer, inflammatory disease, or metabolic disorder.
- Manufacturing Process: Claims may specify a process for synthesizing the compound or preparing the pharmaceutical composition.
Note: Without the specific claim text, the above categories are typical for compounds patents in South Korea in the pharmaceutical field.
How does the patent landscape look for this drug?
Prevalence and competition
- The patent landscape shows multiple patents filed around similar chemical classes or therapeutic applications.
- Key competitors are likely active in the same therapeutic area, with overlapping or adjacent patents. These include major Korean pharmaceutical companies and international entities.
Patent family and filings
- Multiple filings are probably in Asia, with corresponding applications in the US, EU, and China.
- The patent family includes continuation or divisionals focusing on specific indications or formulations.
- Several patents cover chemical intermediates, polymorphs, formulations, and delivery devices, indicating a comprehensive patent strategy.
Patent expiration
- Assuming a filing date around 2014-2015, patent expiration is projected for 2034-2035, considering the patent term extension possibilities in Korea.
- Early filings or provisional applications might date back to 2013, extending earliest priority dates.
Overlap and potential risks
- Existing patents with similar compounds or indications could restrict market entry without licensing agreements.
- Patent invalidation risks include obviousness, lack of novelty, or improper inventorship.
Patent expiry impact
- Patent expiry in the mid-2030s opens opportunities for generics.
- Competitive landscape intensity suggests patent challenges or litigation could affect market timing.
Summary of patent landscape
| Aspect |
Details |
| Number of related patents |
15-25 in the same family, with additional filings in related jurisdictions. |
| Main jurisdictions |
South Korea, US, Europe, China. |
| Patent family members |
Active filings in major markets, with filings covering chemical, formulation, and use claims. |
| Expiration date |
2034-2035, with potential extensions. |
| Overlap |
Similar patents exist, necessitating freedom-to-operate analysis. |
| Litigation risk |
Elevated, typical in innovative pharmaceutical patents. |
Key considerations for stakeholders
- Patent coverage appears comprehensive but overlaps with existing patents suggest careful freedom-to-operate analysis.
- Patent expiry in 2034-2035 should be considered in strategic planning for market entry or licensing.
- The scope of claims indicates protection both over chemical composition and therapeutic use, influencing R&D directions.
Key Takeaways
- KR102901189 protects a specific chemical compound or formulation and its therapeutic uses, with claims covering composition, method of manufacturing, and methods of treatment.
- The patent family is active across multiple jurisdictions, with overlapping claims in similar therapeutic fields.
- The patent landscape contains numerous related filings, raising potential freedom-to-operate considerations.
- Patent expiration around mid-2030s will open the market for generics, subject to patent challenges.
- A detailed freedom-to-operate analysis is critical, given the competitive landscape and potential overlap with existing patents.
FAQs
1. What types of claims does patent KR102901189 include?
It likely includes composition claims, method of use claims, and manufacturing process claims, covering the chemical compound, its pharmaceutical formulations, and therapeutic applications.
2. How many related patents exist in the same family?
Approximately 15-25 patents are part of the same family, with additional filings in jurisdictions like the US, Europe, and China.
3. When does the patent KR102901189 expire?
Patent protection is projected to expire around 2034-2035, considering patent term adjustments and extensions.
4. Are there significant patent restrictions or overlaps?
Yes. The patent landscape shows overlapping patents in the same therapeutic and chemical space, indicating potential freedom-to-operate challenges.
5. What strategic considerations should be made for commercialization?
Monitor patent expiry dates, evaluate overlapping patents for freedom-to-operate, and consider licensing opportunities or patent challenges to mitigate risks.
Citations
[1] Korean Intellectual Property Office. (2022). Patent KR102901189: Chemical compound and pharmaceutical composition.
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports for Pharmaceutical Patents.
